Goodwin Procter advised Ducentis BioTherapeutics on the deal. Ducentis BioTherapeutics announced its acquisition by Arcutis Biotherapeutics for up to $400 million. Ducentis BioTherapeutics, a portfolio company of...
Goodwin Procter advised Ducentis BioTherapeutics on the deal. Ducentis BioTherapeutics announced its acquisition by Arcutis Biotherapeutics for up to $400 million. Ducentis BioTherapeutics, a portfolio company of...
You must be a Standard 1 Year member to access this content.